Document Detail


NDM-4 metallo-β-lactamase with increased carbapenemase activity from Escherichia coli.
MedLine Citation:
PMID:  22252797     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
A clinical Escherichia coli isolate resistant to all β-lactams, including carbapenems, expressed a novel metallo-β-lactamase (MBL), NDM-4, differing from NDM-1 by a single amino acid substitution (Met154Leu). NDM-4 possessed increased hydrolytic activity toward carbapenems and several cephalosporins compared to that of NDM-1. This amino acid substitution was not located in the known active sites of NDM-1, indicating that remote amino acid substitutions might also play a role in the extended activity of this MBL.
Authors:
Patrice Nordmann; Anne E Boulanger; Laurent Poirel
Related Documents :
6201097 - Comparison of the amino acid compositions and antigenic properties of spiralins purifie...
18155317 - Preliminary study on biomarkers for the fungal resistance in vitis vinifera leaves.
25386527 - Qualitative histological evaluation of hard and soft tissue components of human permane...
16665397 - Development at cold-hardening temperatures : the structure and composition of purified ...
701287 - Mechanism of luteinizing hormone regulation of prostaglandin synthesis in rat granulosa...
8460917 - In vitro activities of ceftriaxone and fusidic acid against 13 isolates of coxiella bur...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't     Date:  2012-01-17
Journal Detail:
Title:  Antimicrobial agents and chemotherapy     Volume:  56     ISSN:  1098-6596     ISO Abbreviation:  Antimicrob. Agents Chemother.     Publication Date:  2012 Apr 
Date Detail:
Created Date:  2012-03-19     Completed Date:  2012-06-28     Revised Date:  2013-06-26    
Medline Journal Info:
Nlm Unique ID:  0315061     Medline TA:  Antimicrob Agents Chemother     Country:  United States    
Other Details:
Languages:  eng     Pagination:  2184-6     Citation Subset:  IM    
Affiliation:
Service de Bactériologie-Virologie, INSERM U914, Emerging Resistance to Antibiotics, Hôpital de Bicêtre, Assistance Publique/Hôpitaux de Paris, Faculté de Médecine et Université Paris-Sud, Kremlin-Bicêtre, France. nordmann.patrice@bct.aphp.fr
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Amino Acid Substitution
Anti-Bacterial Agents / pharmacology
Bacterial Proteins / genetics,  metabolism*
Carbapenems / pharmacology
Cephalosporins / pharmacology
Cloning, Molecular
DNA, Bacterial / genetics
Escherichia coli / drug effects,  enzymology*,  genetics
Humans
Hydrolysis
Kinetics
Microbial Sensitivity Tests
Plasmids / genetics
Polymerase Chain Reaction
Urinary Tract Infections / microbiology
beta-Lactamases / genetics,  metabolism*
Chemical
Reg. No./Substance:
0/Anti-Bacterial Agents; 0/Bacterial Proteins; 0/Carbapenems; 0/Cephalosporins; 0/DNA, Bacterial; EC 3.5.2.6/beta lactamase NDM-4, E coli; EC 3.5.2.6/beta-Lactamases; EC 3.5.2.6/carbapenemase
Comments/Corrections

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Switching from enoxaparin to dabigatran etexilate: pharmacokinetics, pharmacodynamics, and safety pr...
Next Document:  Population pharmacokinetics of telavancin in healthy subjects and patients with infections.